Larynx protection trial with tislelizumab and chemo
Part of Cancer, Ear, nose & throat, Lungs & breathing, Mouth & dental clinical trials.
This trial is testing a drug called tislelizumab combined with standard chemotherapy to help people with advanced throat cancer keep their voice box (larynx). The goal is to shrink the tumor enough so surgery may not be needed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced throat cancer (laryngeal or hypopharyngeal) that can still be removed surgically.
- You are between 18 and 70 years old.
- You have not had any cancer treatment (surgery, chemo, radiation, or immunotherapy) in the last 6 months.
- You do not have any active autoimmune diseases like lupus, rheumatoid arthritis, or severe asthma.
- You have not had a severe infection (like pneumonia needing hospitalization) in the last month.
- You do not have any other cancer diagnosed in the last 5 years (except for very early skin cancer or treated thyroid cancer).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a drug called pembrolizumab (Keytruda) can help people with advanced throat cancer avoid removal of the voice box. You may be eligible if you have a specific type of larynx or hypopharynx cancer that hasn't been treated with radiation or immunotherapy before.
This trial tests a new approach to treat throat cancer while trying to preserve your larynx (voice box). It combines chemotherapy drugs and an immunotherapy drug before surgery or radiation. The goal is to see if this can help you avoid needing to have your larynx removed.
This trial tests whether giving the immunotherapy drug tislelizumab with chemotherapy before surgery can help people with advanced head and neck cancer. The goal is to shrink the tumor enough to remove it completely during surgery.
This trial tests whether giving tislelizumab (an immunotherapy) along with chemotherapy before and after surgery can help people with a type of esophageal cancer called squamous cell carcinoma. The goal is to see if this combination improves outcomes for patients whose cancer is in the chest and can be removed with surgery.
This trial tests whether adding the immunotherapy drug tislelizumab to standard chemotherapy after surgery can help prevent esophageal cancer from coming back. It is for people whose cancer had spread to lymph nodes at the time of surgery.
This trial tests combining the immunotherapy drug tislelizumab with radiation therapy for people with advanced non-squamous non-small cell lung cancer that hasn't been treated before. It aims to see if this combination helps control the cancer better than standard treatments.
Hear when a new Laryngeal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.